Halozyme Therapeutics HALO

HealthcareMarket cap $13B2 connections

Halozyme's ENHANZE drug delivery technology - using an enzyme to create temporary space under the skin - converts IV infusions into quick subcutaneous injections. Roche, Pfizer, Janssen, and Argenx pay Halozyme royalties to use ENHANZE for their drugs. A 4-hour IV infusion becomes a 5-minute injection, transforming patient experience.

Open Halozyme Therapeutics's Company Hub Simulate a merger Supply chain See it on the map

Partners 2

Strategic partnerships, joint products and alliances

AbbVieHealthcare · $467BAbbVie ENHANZE collaboration with Halozyme
PfizerHealthcare · $163BRoche uses Halozyme ENHANZE for subcutaneous drugs

Other Healthcare companies

Eli Lilly Johnson & Johnson AbbVie Novo Nordisk Merck UnitedHealth Thermo Fisher AstraZeneca Amgen Novartis

Embed this on your site

Show Halozyme Therapeutics's network in an article or report - it updates as our data does.

<iframe src="https://vexmap.com/embed.html?co=HALO" width="600" height="420" style="border:0;border-radius:12px;max-width:100%" title="Halozyme Therapeutics on VexMap" loading="lazy"></iframe>

Preview

Relationships are compiled by VexMap from company filings, announcements and reporting, and last reviewed September 2026. Spotted something wrong? Tell us. Not investment advice.